Literature DB >> 10954661

Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study.

K Timonen1, A L Kariniemi, K M Niemi, A M Teppo, R Tenhunen, R Kauppinen.   

Abstract

BACKGROUND: Erythropoietic protoporphyria (EPP) is an inherited disease caused by deficient activity of ferrochelatase in the heme biosynthetic pathway. Accumulation of protoporphyrins and light exposure results in acute phototoxic skin reactions. The histopathologic findings of the light-exposed skin are thickening of the superficial dermal vessel walls and amorphous deposits around the vessels, but the origin and detailed composition of the perivascular material have been unclear.
OBJECTIVE: The vascular morphology and composition of the perivascular material were studied in the skin samples of patients with EPP.
METHODS: Skin biopsy specimens of 8 patients with EPP representing 7 Finnish EPP families with different genotypes were studied by means of light and electron microscopy and immunohistochemical methods.
RESULTS: The characteristic finding was thickened, periodic acid-Schiff-positive vessel walls caused by concentric reduplication of basal lamina and excess of fine granular material at the basal membrane zone in the superficial dermis. The perivascular deposits in the vicinity of vessel walls had a homogeneous or fine granular appearance without filaments. Direct immunofluorescence showed constant IgG deposits together with IgA, IgM, and C3 in the vessel walls. In immunohistochemistry, collagen IV and laminin could be demonstrated at the vascular basal membrane together with serum amyloid P protein, kappa and lambda light chains, and a 90-kd glycoprotein.
CONCLUSION: The vascular involvement indicates that the blood vessel walls in the papillary dermis are the primary tissues affected during an acute photoreaction. The repeated acute damage and repair processes in the basement membrane zone result in thickening of the vessel walls. Perivascular deposits are a secondary and irreversible phenomenon resulting from the leakage and accumulation of different serum components. These changes were not found in the nonexposed skin, indicating that an increased level of erythrocyte protoporphyrin per se is not responsible for the cutaneous manifestations, but the interaction of solar radiation is mandatory. Amorphous deposits distinguish EPP from variegate porphyria and porphyria cutanea tarda; a histopathologic examination may be a helpful tool in differentiating porphyric and nonporphyric photosensitivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954661     DOI: 10.1067/mjd.2000.107498

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Authors:  Elisabeth I Minder; Jasmin Barman-Aksoezen; Xiaoye Schneider-Yin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria.

Authors:  Yongming Wang; Nathaniel B Langer; George C Shaw; Guang Yang; Liangtao Li; Jerry Kaplan; Barry H Paw; Joseph R Bloomer
Journal:  Exp Hematol       Date:  2011-05-11       Impact factor: 3.084

Review 3.  Severe radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: a literature review.

Authors:  G Brandon Gunn; Karl E Anderson; Abhilasha J Patel; Juan Gallegos; Csilla Kormos Hallberg; Gagan Sood; Sandra S Hatch; Giuseppe Sanguineti
Journal:  Head Neck       Date:  2010-08       Impact factor: 3.147

4.  A case of bilateral scarring of the cheeks in a child.

Authors:  Yk Inchara; T Rajalakshmi; Mary Augustine
Journal:  J Cutan Aesthet Surg       Date:  2010-09

5.  Level of expression of the nonmutant Ferrochelatase allele is a determinant of biochemical phenotype in a mouse model of erythropoietic protoporphyria.

Authors:  Joseph Bloomer; Yongming Wang; Dongquan Chen
Journal:  Gene Regul Syst Bio       Date:  2008-05-29

6.  Erythropoietic protoporphyria without skin symptoms-you do not always see what they feel.

Authors:  Anne L Y Lecluse; Veronica C M Kuck-Koot; Huib van Weelden; Vigfus Sigurdsson; Ingrid M Russel; Jorge Frank; Suzanne G M A Pasmans
Journal:  Eur J Pediatr       Date:  2007-08-21       Impact factor: 3.183

7.  Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.

Authors:  Jasmin Barman-Aksözen; Michèle Nydegger; Xiaoye Schneider-Yin; Anna-Elisabeth Minder
Journal:  Orphanet J Rare Dis       Date:  2020-08-18       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.